InChI=1S/C22H32O4/c1-2-3-10-15-20(23)17-12-8-9-13-18-21(24)16-11-6-4-5-7-14-19-22(25)26/h3,5-13,17-18,20-21,23-24H,2,4,14-16,19H2,1H3,(H,25,26)/b7-5-,9-8+,10-3-,11-6-,17-12-,18-13+/t20-,21-/m1/s1 |
CRDZYJSQHCXHEG-HBMALMRFSA-N |
OC(CC/C=C\C/C=C\C[C@H](/C=C/C=C/C=C\[C@@H](C/C=C\CC)O)O)=O |
|
Bronsted acid
A molecular entity capable of donating a hydron to an acceptor (Bronsted base).
(via oxoacid )
|
|
specialised pro-resolving mediator
A class of cell signaling molecules enzymatically derived from n-3 long chain polyunsaturated fatty acids that have important roles in orchestrating the resolution of tissue inflammation.
human xenobiotic metabolite
Any human metabolite produced by metabolism of a xenobiotic compound in humans.
|
|
specialised pro-resolving mediator
A class of cell signaling molecules enzymatically derived from n-3 long chain polyunsaturated fatty acids that have important roles in orchestrating the resolution of tissue inflammation.
anti-inflammatory agent
Any compound that has anti-inflammatory effects.
neuroprotective agent
Any compound that can be used for the treatment of neurodegenerative disorders.
|
|
View more via ChEBI Ontology
(4Z,7Z,10R,11E,13E,15Z,17R,19Z)-10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoic acid
|
(4Z,7Z,10R,11E,13E,15Z,17R,19Z)-10,17-dihydroxydocosahexaenoic acid
|
ChEBI
|
10(R),17(R)-dihydroxydocosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid
|
ChEBI
|
aspirin-triggered neuroprotectin D1
|
ChEBI
|
AT-(NPD1/PD1)
|
ChEBI
|
AT-NPD1
|
ChEBI
|
AT-PD1
|
ChEBI
|
22110134
|
Reaxys Registry Number
|
Reaxys
|
21867913
|
PubMed citation
|
Europe PMC
|
22542947
|
PubMed citation
|
Europe PMC
|
22566962
|
PubMed citation
|
Europe PMC
|
22690022
|
PubMed citation
|
Europe PMC
|
24262603
|
PubMed citation
|
Europe PMC
|
24520010
|
PubMed citation
|
Europe PMC
|
25139562
|
PubMed citation
|
Europe PMC
|
27121596
|
PubMed citation
|
Europe PMC
|
|